Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported a series of option exercises and share sales. Over March 16–18, 2026, he exercised employee stock options to acquire 107,250 shares of common stock at strike prices between $27.94 and $39.40 per share.
Across the same dates, he sold 107,250 common shares in open-market transactions at weighted-average prices within ranges from $49.34 to $51.15, with details available in the price footnotes. The filing notes that at least one transaction was made under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these transactions, Bhatt directly holds 17,044 Supernus shares.
SUPN reports Form 144 notice filing for proposed sale of Common Stock. The filing lists 57,250 shares associated with an exercise of stock options and identifies Morgan Stanley Smith Barney LLC as the broker-dealer with an execution date of 03/17/2026. It also notes a 10b5-1 sale of 50,000 shares on 03/16/2026 by Padmanabh P. Bhatt.
SUPERNUS PHARMACEUTICALS, INC. President and CEO Jack A. Khattar reported trust-related stock activity in Supernus. On March 13, 2026, a trust associated with him, the KBT Trust, sold a total of 35,000 shares of common stock in open-market transactions at weighted average prices around $50–$52 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025.
On the same date, 12,500 shares were transferred from the KBT Trust to Khattar without consideration, moving from indirect to direct ownership. Following these changes, he held 1,241,144 shares directly and 958,100 shares indirectly through the KBT Trust, indicating a partial, planned reduction in the trust’s holdings while maintaining a substantial overall position.
SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported an open-market sale of 5,369 shares of Common Stock on March 12, 2026. The weighted average sale price was $50.6100 per share, with trades executed between $50.45 and $50.82. Following this transaction, he directly holds 60,413 shares.
SUPN reports a sale of 5,369 shares of Common Stock. The entry lists Morgan Stanley Smith Barney LLC as the broker and describes the shares as restricted stock vesting under a registered plan with a transaction date of 02/22/2025.
SUPN reported a Form 144 disclosure showing an insider disposition. The filing lists a sale by Todd Horich of 4,438 shares of Common Stock on 03/09/2026 for $239,652.00. The filing also shows restricted stock vesting entries of 394 shares on 02/23/2026 and 4,045 shares on 02/28/2026, each described as employee stock unit awards under a registered plan.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported routine equity compensation activity involving Performance Share Units that converted into common stock. He exercised derivative awards covering 38,640 Performance Share Units, receiving the same number of shares of common stock.
To cover tax withholding triggered by this vesting, 16,574 shares of common stock were withheld by the company at $54.73 per share, as described in the footnotes. After these transactions, Khattar held 1,228,644 shares of common stock directly and 1,005,600 shares indirectly through the KBT Trust, reflecting a substantial ongoing ownership position.
Supernus Pharmaceuticals SVP Frank Mottola reported a combination of equity compensation events and a small stock sale. He exercised 3,750 Performance Share Units into common stock, with 1,793 shares withheld by the company to cover taxes upon vesting of those units. Shortly after, he executed an open‑market sale of 1,623 common shares at $53.65 per share. Following these transactions, he directly owns 18,440 shares of common stock, reflecting a routine use of vested equity and partial share sale.